Charles River Laboratories
Fabian Stavenuiter is a Principal Scientist and Research Leader in Translational Biology at Charles River Laboratories, where responsibilities include overseeing multidisciplinary teams on complex in vitro cellular research programs targeting various therapeutic areas such as haemostasis and oncology since April 2019. Prior to this role, Stavenuiter worked as a Specialist in Hemophilia Translational Biology at Novo Nordisk from April 2015 to April 2019, contributing to the development of safe and effective therapies. Stavenuiter also served as a Postdoctoral Research Fellow at The Scripps Research Institute from October 2010 to January 2015, focusing on biochemical assays related to the coagulation system. Educational qualifications include a PhD in Haemostasis/Biochemistry from Sanquin, an M.S. in Biomedical Sciences from Vrije Universiteit Amsterdam, and a B.S. in Biomedical Sciences from Hogeschool Leiden.
This person is not in any teams
This person is not in any offices
Charles River Laboratories
17 followers
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.